MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-27-2026
Establishment Labs Holdings Net Income 2011-2026 | ESTA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Establishment Labs Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -51.1 M | -84.6 M | -78.5 M | -75.2 M | -41.1 M | -38.1 M | -38.2 M | -21.1 M | -34.9 M | -22.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21.1 M | -84.6 M | -48.5 M |
Quarterly Net Income Establishment Labs Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.1 M | -16.6 M | -20.7 M | - | -16.7 M | -17.2 M | -16.2 M | - | -29.3 M | -16.7 M | -11.9 M | - | -18.6 M | -37.1 M | -5.93 M | - | -14.7 M | -5.32 M | -6.95 M | - | -4.24 M | -10.5 M | -17.8 M | - | -12.8 M | -9.04 M | -10.8 M | - | 1.31 M | -5.36 M | -6.53 M | - | -10.7 M | -12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.31 M | -37.1 M | -13.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Inogen
INGN
|
-22.7 M | $ 6.32 | -2.02 % | $ 168 M |  USA |
 |
IRadimed Corporation
IRMD
|
22.5 M | $ 99.89 | 0.69 % | $ 1.27 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
BioSig Technologies
BSGM
|
-10.3 M | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
-9.57 M | $ 1.35 | -0.04 % | $ 21.8 M | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
LivaNova PLC
LIVN
|
-242 M | $ 63.27 | 0.05 % | $ 3.45 B |  Britain |
 |
LENSAR
LNSR
|
-31.4 M | $ 5.71 | -5.93 % | $ 65.8 M | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
AxoGen
AXGN
|
-15.7 M | $ 32.42 | 2.11 % | $ 1.49 B | USA |
 |
CONMED Corporation
CNMD
|
47.1 M | $ 36.72 | 0.25 % | $ 1.14 B | USA |
 |
Medtronic PLC
MDT
|
4.66 B | $ 86.65 | -0.64 % | $ 111 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Electromed
ELMD
|
7.54 M | $ 24.67 | 0.73 % | $ 209 M | USA |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-20.7 M | $ 0.72 | 6.7 % | $ 39.2 M | USA |
 |
Aethlon Medical
AEMD
|
-13.4 M | $ 2.15 | -6.52 % | $ 3.36 M | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
Orthofix Medical
OFIX
|
-92.2 M | $ 11.77 | -0.84 % | $ 466 M |  Curacao |
 |
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 11.48 | 10.66 % | $ 1.55 B | USA |
 |
Myomo
MYO
|
-15.6 M | $ 0.69 | -2.17 % | $ 28.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-53.5 M | $ 2.33 | -4.71 % | $ 137 M | Israel |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | $ 3.85 | 3.08 % | $ 144 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 15.84 | -3.83 % | $ 372 M | USA |
 |
Penumbra
PEN
|
178 M | $ 334.58 | -0.3 % | $ 13 B | USA |
 |
Outset Medical
OM
|
-81.7 M | $ 3.49 | -3.6 % | $ 53.1 K | USA |
 |
Inspire Medical Systems
INSP
|
145 M | $ 51.53 | -1.3 % | $ 1.51 B | USA |
 |
Insulet Corporation
PODD
|
247 M | $ 225.21 | -0.82 % | $ 15.8 B | USA |
 |
Profound Medical Corp.
PROF
|
-30.7 M | $ 5.1 | -5.56 % | $ 180 M | Canada |
 |
Pulmonx Corporation
LUNG
|
-54 M | $ 1.33 | -4.68 % | $ 54.1 M | USA |
 |
Quanterix Corporation
QTRX
|
-107 M | $ 3.68 | -6.73 % | $ 157 M | USA |
 |
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
InspireMD
NSPR
|
-48.8 M | $ 1.8 | 4.05 % | $ 116 M | Israel |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |